GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ianalumab   Click here for help

GtoPdb Ligand ID: 10656

Synonyms: VAY-736 | VAY736
Immunopharmacology Ligand
Compound class: Antibody
Comment: Ianalumab (VAY736) is an investigtional anti-BAFF receptor (TNFRSF13C) monoclonal antibody (mAb) from Novartis [6]. BLAST analysis of peptide sequences from its INN record reveal identical matches with peptide sequences claimed in Novartis patent WO2010007082A1 [4]. The sequence matches suggest that mAb MORO7347 identified in the patent could be VAY736.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Dörner T, Bowman SJ, Fox R, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H et al.. (2025)
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study.
Arthritis Rheumatol, 77 (5): 560-570. [PMID:39557617]
2. Diekhoff T, Fischer T, Schefer Q, Posch MG, Dörner T, Laurent D, Li Y, Wagner FD, Oliver SJ. (2020)
Ianalumab (VAY736) in primary Sjögren's syndrome: assessing disease activity using multi-modal ultrasound.
Clin Exp Rheumatol, 38 Suppl 126 (4): 228-236. [PMID:33095139]
3. Dörner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM, Kamphausen E, Valentin MA, Simonett C, Mooney L et al.. (2019)
Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
Ann Rheum Dis, 78 (5): 641-647. [PMID:30826774]
4. Heusser C, Neugebauer J, Schaadt E, Urlinger S, Woisetschlaeger M. (2010)
Compositions and methods of use for therapeutic antibodies.
Patent number: WO2010007082A1. Assignee: Novartis. Priority date: 17/07/2008. Publication date: 21/01/2010.
5. Mavragani CP, Moutsopoulos HM. (2020)
Sjögren's syndrome: Old and new therapeutic targets.
J Autoimmun, 110: 102364. [PMID:31831255]
6. McWilliams EM, Lucas CR, Chen T, Harrington BK, Wasmuth R, Campbell A, Rogers KA, Cheney CM, Mo X, Andritsos LA et al.. (2019)
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.
Blood Adv, 3 (3): 447-460. [PMID:30737226]